We’re proud to highlight our collaboration with EG 427, a pioneering biotechnology company dedicated to providing safe, efficacious, and affordable therapies for patients with severe localized chronic diseases. Based in Paris, France, EG 427 is unlocking the full potential of non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors as a powerful platform for gene therapy.

Their innovative approach enables the expression of large genes under the control of sophisticated regulatory elements, offering a safe, redosable, and highly precise gene therapy solution. This groundbreaking platform is transforming the treatment landscape for neuronal disorders and other conditions with significant unmet needs.

Here’s what Samuel Salot, COO at EG 427, shared about his experience working with INITS:

"Working with INITS has been a seamless and highly rewarding experience. Their professionalism, technical expertise, and commitment to delivering quality services have greatly contributed to the success of our project. We highly appreciate their collaborative approach and responsiveness, which have helped us meet our goals efficiently. I would strongly recommend INITS to any company looking for a reliable and innovative partner."

At INITS, we’re dedicated to supporting our partners at every step of their journey. Our core values — Synergy, Audacity, and Integrity — drive us to deliver bespoke, high-quality solutions. From tackling complex CMC challenges to offering strategic regulatory guidance, our mission is to empower innovative projects like those of EG 427.

🙏 Thank you, EG 427, for your trust and partnership. We’re thrilled to continue this collaboration and shape the future of gene therapy together!

#Partnership #GeneTherapy #CMC #Biotechnology #Innovation #Biomanufacturing #Collaboration